Tenderwize
Back to tender search

Infliximab medicinal products (injection solution)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2027 · 378 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Infliximab (ATC: L04AB02 - in der Darreichungsform Injektionslösung)

58/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

58 / 100

Complexity

42 / 100

Risk factors

The structured data says electronic submission is not allowed, while the XML notice says contract documents may be sent...

The structured deadline in the notice and the XML timestamps are not fully aligned (deadline date versus occurrence tim...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for pharmaceutical products containing infliximab (ATC L04AB02) in injection solution form.
  • Open-house access model with uniform contract terms and equal access for eligible companies.
Show full summary

This is an open-house style notice for non-exclusive discount agreements for infliximab medicinal products (ATC L04AB02, injection solution) in Germany. The contracting buyer is AOK Sachsen-Anhalt. The notice states that any eligible pharmaceutical company may join on the same terms, with no individual negotiations and no exclusivity. The contract can start from 2025-11-01 and ends on 2027-10-31 regardless of start date. No contract value is provided. Procurement documents appear available, but only the XML notice text was provided for analysis.

Risks

The structured data says electronic submission is not allowed, while the XML notice says contract documents may be sent...

The structured deadline in the notice and the XML timestamps are not fully aligned (deadline date versus occurrence tim...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Administrative

  • Interested pharmaceutical companies must request the participation documents and the contract from the contact address.
  • The participation documents must be completed in full and signed.
  • The XML notice indicates submission of contract documents by post is possible and also electronically as PDF with a qualified electronic signature via email to...

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Infliximab medicinal products (injection solution)

Single lot for non-exclusive discount agreements for finished medicinal products containing infliximab (ATC L04AB02) in injection solution form. Open-house model: any eligible pharmaceutical company may conclude or join a contract under identical conditions. No exclusivity and no individual negotiations. Earliest contract start is 2025-11-01; maximum duration is 24 months; contract ends on 2027-10-31 regardless of start date. The notice also says contracts may end early if exclusive tenders are later launched under the applicable rules.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Deadline

Deadline Aug 30, 2027

Procurement Details

Publication date
17 Sep 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
612510-2025

Documents (1)

Similar tenders